Most biopharma and life sciences hedge funds continued to struggle in May in what is shaping up to be one of the worst years in recent memory for the strategy. Many funds are down by double-digit rates this year, including a few that are off
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.